AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22282958
Drug: IBN/SNAC formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBN/SNAC formulation co-administered with metformin
Trial: 19761951
Drug: Group Interpersonal
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Interpersonal Psychotherapy plus massage therapy (20 min sessions, once per week for 6 weeks)
Trial: 10460375
Drug: Iodixanol (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol (270 mg I/ml)
Trial: 7599293
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone 0.2 IU
Trial: 7599293
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone 0.7 IU
Trial: 7599293
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone 0.02 IU
Trial: 7599293
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone 2 IU
Trial: 29526833
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose (MD) of ticagrelor (C-600 mg-24h)
Trial: 29526833
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose (MD) of ticagrelor (C-600 mg-12h)
Trial: 29526833
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d maintenance dose (C-75 mg-24h)
Trial: 29526833
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily maintenance dose (T-90 mg twice daily)
Trial: 25330838
Drug: Transcranial bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial bright light treatment via ear canals (1 lumen/0.72 mW/cm(2))
Trial: 25330838
Drug: Transcranial bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial bright light treatment via ear canals (4 lumens/2.881 mW/cm(2))
Trial: 25330838
Drug: Transcranial bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial bright light treatment via ear canals (9 lumens/6.482 mW/cm(2))
Trial: 21108056
Drug: 800 ml
RxNorm normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 ml of 12.5% glucose solution the night before surgery and 200 ml two hours before surgery (Group A)
Trial: 12357299
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg EPI/30 ml saline 19 times over 1 year (arm A)
Trial: 12357299
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg EPI/30 ml 12 times over 5 months (arm B)
Trial: 9796041
Drug: DTaP or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP or DTP vaccine
Trial: 9796041
Drug: Pertactin value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertactin value < 7 EU ml‐1
Trial: 9796041
Drug: Pertactin value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertactin value >= 7 EU ml‐1 and PT value >= 66 EU ml‐1
Trial: 9796041
Drug: Pertactin value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertactin value >= 7 EU ml‐1 and PT value < 66 EU ml‐1
Trial: 9796041
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of antibody to pertactin, PT and fimbriae‐2
Trial: 9796041
Drug: Multicomponent vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent vaccines containing pertactin and fimbriae
Trial: 7636684
Drug: Rice-based oral
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-based oral rehydration solution (50 g/L)
Trial: 7636684
Drug: Glucose-based WHO/UNICEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-based WHO/UNICEF solution
Trial: 2613606
Drug: Ceftazidime (monotherapy)
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime (monotherapy)
Trial: 2613606
Drug: Ceftazidime plus
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime plus tobramycin (combination therapy)
Trial: 31669625
Drug: Anagliptin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagliptin (200 mg/day)
Trial: 25627123
Drug: Split-thickness autograft
RxNorm normalized name: THICK & EASY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-thickness autograft combined with harvested skin cell suspension
Trial: 17440685
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml flush of 5% povidone iodine (flush group)
Trial: 8005548
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) plus ethinyl estradiol (EE)
Trial: 23359581
Drug: Take Care
RxNorm normalized name: ALCOHOL 62 mL in 100 mL TOPICAL SPRAY [Take Care Clinic Instant Hand Sanitizer Spray]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take Care technique (early surfactant treatment via thin catheter)
Trial: 19395578
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg infliximab and 5 mg/kg infliximab
Trial: 16984575
Drug: Wound gel
RxNorm normalized name: Hylase Wound Gel
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wound gel with gauze dressings
Trial: 12764908
Drug: Tetramethylpyrazine (TMP)
RxNorm normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetramethylpyrazine (TMP) 3 mg/kg intravenously after anesthesia induction and 1 mg/kg in oxygenator during CPB
Trial: 30096265
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (non-XPSG)
Trial: 12127464
Drug: Standard outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard outpatient alcoholism treatment (ST)
Trial: 12127464
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment (MT)
Trial: 1693111
Drug: Otomize (neomycin/dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otomize (neomycin/dexamethasone spray)
Trial: 28630183
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation
Trial: 26423050
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL mepivacaine 1.5%
Trial: 26423050
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL mepivacaine 1%
Trial: 26423050
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL mepivacaine 1.5%
Trial: 20934685
Drug: Cognitive-behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural treatment (n=17)
Trial: 11369156
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg intravenous infusion over one hour)
Trial: 11369156
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution intravenous infusion over one hour)
Trial: 8988992
Drug: Propofol-based anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-based anesthesia (5 mg.kg‐1.h‐1 prior to sternotomy, 3 mg.kg‐1.h‐1 thereafter)
Trial: 30950283
Drug: Morning Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning Training (MG)
Trial: 22766268
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human bone morphogenetic protein‐7 (rhBMP‐7) with deproteinised bone substitute (0.5 g)
Trial: 22766268
Drug: deproteinised bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deproteinised bone alone (2.0 g)
Trial: 20147570
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg dDAVP combined with 10 µg hCRH
Trial: 20147570
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg dDAVP combined with 30 µg hCRH
Trial: 20147570
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg dDAVP alone
Trial: 20147570
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg hCRH administered two hours after 10 µg dDAVP
Trial: 20147570
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg dDAVP followed by 100 µg hCRH
Trial: 11171729
Drug: IV combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV combination of diltiazem and digoxin
Trial: 9603556
Drug: Presurgical orthopedic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presurgical orthopedic treatment (PSOT)
Trial: 9603556
Drug: Non-presurgical orthopedic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-presurgical orthopedic treatment (non-PSOT)
Trial: 15121648
Drug: Sertraline (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (both doses)
Trial: 11698228
Drug: Protease Inhibitors
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease Inhibitors (PI group)
Trial: 3041555
Drug: Endoscopic injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injections of OK-432 plus systemic treatment (5-fluorouracil)
Trial: 30782687
Drug: LDL-C reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C reduction to <120-160 mg/dL (group A)
Trial: 30782687
Drug: LDL-C reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C reduction to <70 mg/dL (group B)
Trial: 28087548
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (laser iridotomy followed by medical therapy and glaucoma surgery)
Trial: 23142493
Drug: Oral methylphenidate
RxNorm normalized name: methylphenidate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylphenidate (MPH) 35 mg (approximately 0.5 mg/kg)
Trial: 18481293
Drug: Corticosteroids administered
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids administered before biopsy
Trial: 18481293
Drug: No corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No corticosteroids administered before biopsy
Trial: 15946237
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of niacinamide
Trial: 7766741
Drug: Rifaximin 400
RxNorm normalized name: Rifaximin 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 400 mg b.d. for 7 days every month plus glucomannan 2 g/day
Trial: 7766741
Drug: Placebo two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo two tablets b.d. for 7 days every month plus glucomannan 2 g/day
Trial: 12970233
Drug: Amiodarone (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (intravenous infusion for the first 24 hours at 1050 mg total, followed by oral therapy for 4 postoperative days at 4800 mg total)
Trial: 29882203
Drug: Niclosamide (NCL)
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niclosamide (NCL) 1000 mg/day
Trial: 29882203
Drug: Lactose (placebo)
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (placebo) 1000 mg/day
Trial: 22630091
Drug: Dexamethasone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (single dose perioperative intravenous steroid)
Trial: 22630091
Drug: No steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroid (Control group)
Trial: 20416042
Drug: TECNOB program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TECNOB program (hospital-based intensive treatment for 1 month including diet therapy, physical training, and psychological counseling)
Trial: 20416042
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (hospital-based treatment only)
Trial: 12544638
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (Cr) supplementation (20 g/d for 5 days, then 3 g/d for 28 days)
Trial: 6394514
Drug: Chlordiazepoxide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (200 mg daily for the first two days, then adjusted based on symptom relief)
Trial: 6394514
Drug: Tiapride (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapride (400 mg daily for the first two days, then adjusted based on symptom relief)
Trial: 30470259
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (10 mg/kg) of liposomal amphotericin B (L-AmB) given with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day)
Trial: 30470259
Drug: Seven days
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven days of amphotericin B deoxycholate (1 mg/kg/day) given alongside seven days of flucytosine (100 mg/kg/day) followed by seven days of fluconazole (1200 mg/day)
Trial: 30470259
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (10 mg/kg) of L-AmB
Trial: 10025892
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two target genes (TcRgamma and TcRdelta) for monitoring minimal residual disease (MRD)
Trial: 2401249
Drug: ACC‐9653 (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC‐9653 (375 mg/5 ml; 232.87 mg free acid)
Trial: 2401249
Drug: PHT sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHT sodium (250 mg/5 ml; 229.95 mg free acid)
Trial: 22319064
Drug: Abciximab administered
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab administered in the ambulance (ambulance group, n=127)
Trial: 22319064
Drug: Abciximab administered
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab administered in the catheterization laboratory (hospital group, n=129)
Trial: 17908370
Drug: Disease-modifying drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying drugs (DMDs)
Trial: 15763392
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg per day for 4 weeks, then 10 mg per day for another 4 weeks)
Trial: 1958007
Drug: Budesonide (BU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (BU), 1200 micrograms daily, intranasally for 14 days
Trial: 1958007
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BE), 400 micrograms daily, intranasally for 14 days
Trial: 30916463
Drug: Methadone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone treatment (for methadone-randomized individuals)
Trial: 30916463
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment (for buprenorphine-randomized individuals)
Trial: 22264303
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (10 grams with normal saline)
Trial: 19172129
Drug: Galacto-oligosaccharides (GOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galacto-oligosaccharides (GOS) 5 g/L
Trial: 9771245
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of inhaled steroids
Trial: 7829006
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate (15 mg/kg per day) for a month
Trial: 7525446
Drug: Post chemotherapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post chemotherapy GCSF
Trial: 748987
Drug: Vaginal 15-methyl-PGF2alpha
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal 15-methyl-PGF2alpha methyl ester (3.0 mg)
Trial: 748987
Drug: Intra-amniotic PGF2alpha
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic PGF2alpha (50 mg)
Trial: 22507444
Drug: Placebo vibratory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vibratory treatment (Control Group)
Trial: 15782425
Drug: 7.5% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% CO2 inhalation for 20 min
Trial: 15782425
Drug: Air inhalation
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air inhalation for 20 min
Trial: 7582380
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (751 mg/l naringin)
Trial: 6997537
Drug: KW-1062 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-1062 at 240 mg/day
Trial: 6997537
Drug: KW-1062 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-1062 at 360 mg/day
Trial: 6997537
Drug: KW-1062 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-1062 (both doses)
Trial: 24592747
Drug: Tocotrienol-rich fraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocotrienol-rich fraction (TRF) of palm oil, 100 mg daily from early second trimester until delivery
Trial: 22847319
Drug: Tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin cream products (three concentrations)
Trial: 22847319
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel products (two concentrations)
Trial: 22847319
Drug: Tretinoin (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin (same concentration) in different vehicles (gel vs. cream)
Trial: 14962945
Drug: Subantimicrobial doses
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial doses of doxycycline (SDD) 20 mg twice daily
Trial: 12166350
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg midazolam intramuscularly
Trial: 12166350
Drug: No pre‐medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre‐medication
Trial: 9856369
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg sustained-release indapamide
Trial: 7596722
Drug: Amoxicillin for
RxNorm normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin for days 1 through 10, then amoxicillin for days 11 through 20
Trial: 7596722
Drug: Amoxicillin for
RxNorm normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin for days 1 through 10, then amoxicillin-clavulanate for days 11 through 20
Trial: 7596722
Drug: Amoxicillin for
RxNorm normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin for days 1 through 10, then placebo for either amoxicillin or amoxicillin-clavulanate for days 11 through 20
Trial: 2229526
Drug: terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbinafine 1% cream
Trial: 2229526
Drug: placebo (cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (cream vehicle)
Trial: 873028
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg amitriptyline once daily
Trial: 873028
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nortriptyline with 1-5 mg fluphenazine once daily
Trial: 17396617
Drug: Oral trapidil
RxNorm normalized name: trapidil
DrugBank: Trapidil (DB09283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trapidil (200 mg)
Trial: 17396617
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide dinitrate (20 mg)
Trial: 17396617
Drug: Intravenous trapidil
RxNorm normalized name: trapidil
DrugBank: Trapidil (DB09283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trapidil (100 mg)
Trial: 12085418
Drug: Verapamil SR/Trandolapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil SR/Trandolapril 180/2 mg/day (VT)